Page 2045 - Williams Hematology ( PDFDrive )

2020 Part XII: Hemostasis and Thrombosis Chapter 117: Thrombocytopenia 2021

125. Takahashi R, Sekine N, Nakatake T: Influence of monoclonal antiplatelet glycoprotein 159. Sarpatwari A, Bennett D, Logie JW, et al: Thromboembolic events among adult patients
antibodies on in vitro human megakaryocyte colony formation and proplatelet forma- with primary immune thrombocytopenia in the United Kingdom General Practice
tion. Blood 93:1951–1958, 1999. Research Database. Haematologica 95:1167–1175, 2010.
126. Kelemen E, Cserhati I, Tanos B: Demonstration and some properties of human throm- 160. Ruggeri M, Tosetto A, Palandri F, et al: Thrombotic risk in patients with primary
bopoietin in thrombocythaemic sera. Acta Haematol 20:350–355, 1958. immune thrombocytopenia is only mildly increased and explained by personal and
127. Kuter DJ: Milestones in understanding platelet production: A historical overview. Br J treatment-related risk factors. J Thromb Haemost 12:1266–1273, 2014.
Haematol 165:248–258, 2015. 161. Burstein SA, Downs T, Friese P, et al: Thrombocytopoiesis in normal and sublethally
128. Kaushansky K: Thrombopoietin: The primary regulator of megakaryocyte and platelet irradiated dogs: Response to human interleukin-6. Blood 80:420–428, 1992.
production. Thromb Haemost 74:521–525, 1995. 162. Khan I, Zucker-Franklin D, Karpatkin S: Microthrombocytosis and platelet fragmenta-
129. Chang M, Qian JX, Lee SM, et al: Tissue uptake of circulating thrombopoietin is tion associated with idiopathic/autoimmune thrombocytopenic purpura. Br J Haematol
increased in immune-mediated compared with irradiated thrombocytopenic mice. 31:449–460, 1975.
Blood 93:2515–2524, 1999. 163. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC: Bernard-Soulier syndrome.
130. Kosugi S, Kurata Y, Tomiyama Y, et al: Circulating thrombopoietin level in chronic Blood 91:4397–4418, 1998.
immune thrombocytopenic purpura. Br J Haematol 93:704–706, 1996. 164. Rodgers RP, Levin J: A critical reappraisal of the bleeding time. Semin Thromb Hemost
131. Kuter DJ: Thrombopoietin and thrombopoietin mimetics in the treatment of thrombo- 16:1–20, 1990.
cytopenia. Annu Rev Med 60:193–206, 2009. 165. Hughes M, Webert K, Kelton JG: The use of electron microscopy in the investigation of
132. Porcelijn L, Folman CC, Bossers B, et al: The diagnostic value of thrombopoietin level the ultrastructural morphology of immune thrombocytopenic purpura platelets. Semin
measurements in thrombocytopenia. Thromb Haemost 79:1101–1105, 1998. Hematol 37:222–228, 2000.
133. Gouin-Thibault I, Cassinat B, Chomienne C, et al: Is the thrombopoietin assay useful 166. Evans RS, Takahashi K, Duane RT, et al: Primary thrombocytopenic purpura and
for differential diagnosis of thrombocytopenia? Analysis of a cohort of 160 patients acquired hemolytic anemia; evidence for a common etiology. AMA. Arch Intern Med
with thrombocytopenia and defined platelet life span. Clin Chem 47:1660–1665, 2001. 87:48–65, 1951.
134. Kuter DJ, Bussel JB, Lyons RM, et al: Efficacy of romiplostim in patients with chronic 167. Stasi R, Stipa E, Masi M, et al: Long-term observation of 208 adults with chronic idio-
immune thrombocytopenic purpura: A double-blind randomised controlled trial. pathic thrombocytopenic purpura. Am J Med 98:436–442, 1995.
Lancet 371:395–403, 2008. 168. Sailer T, Lechner K, Panzer S, et al: The course of severe autoimmune thrombocytope-
135. Psaila B, Bussel JB: Refractory immune thrombocytopenic purpura: Current strategies nia in patients not undergoing splenectomy. Haematologica 91:1041–1045, 2006.
for investigation and management. Br J Haematol 143:16–26, 2008. 169. George JN, Raskob GE: Idiopathic thrombocytopenic purpura: Diagnosis and manage-
136. Bussel JB, Kuter DJ, Aledort LM: A randomized trial of avatrombopag, an investiga- ment. Am J Med Sci 316:87–93, 1998.
tional thrombopoietin-receptor agonist, in persistent and chronic immune thrombocy- 170. Baumann MA, Menitove JE, Aster RH, Anderson T: Urgent treatment of idiopathic
topenia. Blood 123:3887–3897, 2014. thrombocytopenic purpura with single-dose gammaglobulin infusion followed by
137. Laster AJ, Conley CL, Kickler TS, et al: Chronic immune thrombocytopenic purpura in platelet transfusion. Ann Intern Med 104:808–809, 1986.
monozygotic twins: Genetic factors predisposing to ITP. N Engl J Med 307:1495–1498, 171. Larsen OH, Stentoft J, Radia D, et al: Combination of recombinant factor VIIa and
1982. fibrinogen corrects clot formation in primary immune thrombocytopenia at very low
138. Bizzaro N: Familial association of autoimmune thrombocytopenia and hyperthyroid- platelet counts. Br J Haematol 160:228–236, 2013.
ism. Am J Hematol 39:294–298, 1992. 172. Salama A, Rieke M, Kiesewetter H, von Depka H: Experiences with recombinant FVIIa
139. Karpatkin S, Fotino M, Winchester R: Hereditary autoimmune thrombocytopenic pur- in the emergency treatment of patients with autoimmune thrombocytopenia: A review
pura: An immunologic and genetic study. Ann Intern Med 94:781–782, 1981. of the literature. Ann Hematol 88:11–15, 2009.
140. Stanworth SJ, Turner DM, Brown J, et al: Major histocompatibility complex suscepti- 173. Wanachiwanawin W, Piankijagum A, Sindhvananda K, et al: Emergency splenectomy
bility genes and immune thrombocytopenic purpura in Caucasian adults. Hematology in adult idiopathic thrombocytopenic purpura. A report of seven cases. Arch Intern
7:119–121, 2002. Med 149:217–219, 1989.
141. Evers KG, Thouet R, Haase W, Kruger J: HLA frequencies and haplotypes in children 174. Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ: Mechanisms of response to treatment
with idiopathic thrombocytopenic purpura (ITP). Eur J Pediatr 129:267–272, 1978. in autoimmune thrombocytopenic purpura. N Engl J Med 320:974–980, 1989.
142. Pavkovic M, Georgievski B, Cevreska L, et al: CTLA-4 exon 1 polymorphism in patients 175. Bussel JB: Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol
with autoimmune blood disorders. Am J Hematol 72:147–149, 2003. 37:261–266, 2000.
143. Foster CB, Zhu S, Erichsen HC, et al: Polymorphisms in inflammatory cytokines and 176. Kitchens CS: Amelioration of endothelial abnormalities by prednisone in experimental
Fcgamma receptors in childhood chronic immune thrombocytopenic purpura: A pilot thrombocytopenia in the rabbit. J Clin Invest 60:1129–1134, 1977.
study. Br J Haematol 113:596–599, 2001. 177. George JN, Woolf SH, Raskob GE: Idiopathic thrombocytopenic purpura: A guideline
144. George JN, Woolf SH, Raskob GE, et al: Idiopathic thrombocytopenic purpura: A prac- for diagnosis and management of children and adults. American Society of Hematol-
tice guideline developed by explicit methods for the American Society of Hematology. ogy. Ann Med 30:38–44, 1998.
Blood 88:3–40, 1996. 178. George JN, Vesely SK: Immune thrombocytopenic purpura—Let the treatment fit the
145. Guidelines for the investigation and management of idiopathic thrombocytopenic pur- patient. N Engl J Med 349:903–905, 2003.
pura in adults, children and in pregnancy. Br J Haematol 120:574–596, 2003. 179. Mazzucconi MG, Francesconi M, Fidani P, et al: Treatment of idiopathic thrombocy-
146. Rodeghiero F, Stasi R, Gernsheimer T, et al: Standardization of terminology, definitions topenic purpura (ITP): Results of a multicentric protocol. Haematologica 70:329–336,
and outcome criteria in immune thrombocytopenic purpura of adults and children: 1985.
Report from an international working group. Blood 113:2386–2393, 2009. 180. Bellucci S, Charpak Y, Chastang C, Tobelem G: Low doses v conventional doses of cor-
147. Provan D, Stasi R, Newland AC, et al: International consensus report on the investi- ticoids in immune thrombocytopenic purpura (ITP): Results of a randomized clinical
gation and management of primary immune thrombocytopenia. Blood 115:168–186, trial in 160 children, 223 adults. Blood 71:1165–1169, 1988.
2010. 181. Ozsoylu S, Irken G, Karabent A: High-dose intravenous methylprednisolone for acute
148. Neunert C, Lim W, Crowther M, et al: The American Society of Hematology 2011 evi- childhood idiopathic thrombocytopenic purpura. Eur J Haematol 42:431–435, 1989.
dence-based practice guideline for immune thrombocytopenia. Blood 117:4190–4207, 2011. 182. Ozsoylu S, Sayli TR, Ozturk G: Oral megadose methylprednisolone versus intravenous
149. Schoonen WM, Kucera G, Coalson J, et al: Epidemiology of immune thrombocytopenic immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatr
purpura in the General Practice Research Database. Br J Haematol 145:235–244, 2009. Hematol Oncol 10:317–321, 1993.
150. Cortelazzo S, Finazzi G, Buelli M, et al: High risk of severe bleeding in aged patients 183. Albayrak D, Islek I, Kalayci AG, Gurses N: Acute immune thrombocytopenic purpura:
with chronic idiopathic thrombocytopenic purpura. Blood 77:31–33, 1991. A comparative study of very high oral doses of methylprednisolone and intravenously
151. Frederiksen H, Schmidt K: The incidence of idiopathic thrombocytopenic purpura in administered immune globulin. J Pediatr 125:1004–1007, 1994.
adults increases with age. Blood 94:909–913, 1999. 184. Cheng Y, Wong RS, Soo YO, et al: Initial treatment of immune thrombocytopenic
152. George JN, el-Harake MA, Raskob GE: Chronic idiopathic thrombocytopenic purpura. purpura with high-dose dexamethasone. N Engl J Med 349:831–836, 2003.
N Engl J Med 331:1207–1211, 1994. 185. Stasi R, Brunetti M, Pagano A: Pulsed intravenous high-dose dexamethasone in adults
153. McMillan R: Therapy for adults with refractory chronic immune thrombocytopenic with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis 26:582–586,
purpura. Ann Intern Med 126:307–314, 1997. 2000.
154. Schattner E, Bussel J: Mortality in immune thrombocytopenic purpura: Report of seven 186. Mazzucconi MG, Fazi P, Bernasconi S: Therapy with high dose dexamethasone
cases and consideration of prognostic indicators. Am J Hematol 46:120–126, 1994. (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic
155. Portielje JE, Ewstentdorp RG, Kluin-Nelemans HC: Morbidity and mortality in adults purpura: A GIMEMA experience. Blood 109:1401–1407, 2007.
with idiopathic thrombocytopenic purpura. Blood 97:2549–2554, 2001. 187. Alpdogan O, Budak-Alpdogan T, Ratip S: Efficacy of high-dose methylprednisolone as
156. McIntyre OR, Ebaugh FG Jr: Palpable spleens in college freshmen. Ann Intern Med a first-line therapy in adult patients with idiopathic thrombocytopenic purpura. Br J
66:301–306, 1967. Haematol 103:1061–1063, 1998.
157. Newton JL, Reese JA, Watson SI, et al: Fatigue in adult patients with primary immune 188. Bell WR Jr: Long-term outcome of splenectomy for idiopathic thrombocytopenic
thrombocytopenia. Eur J Haematol 86:420–429, 2011. purpura. Semin Hematol 37:22–25, 2000.
158. Blankenship JC, Tasissa G, O’Shea JC, et al: Effect of glycoprotein IIb/IIIa receptor inhi- 189. Kojouri K, Vesely SK, Terrell DR, George JN: Splenectomy for adult patients with idio-
bition on angiographic complications during percutaneous coronary intervention in pathic thrombocytopenic purpura: A systemic review to assess long-term platelet count
the ESPRIT trial. J Am Coll Cardiol 38:653–658, 2001. responses, prediction of response, and surgical complications. Blood 104:2623–2635, 2004.

Kaushansky_chapter 117_p1993-2024.indd 2020 9/21/15 2:34 PM